Soleno Therapeutics (SLNO) Stock Forecast, Price Target & Predictions
SLNO Stock Forecast
Soleno Therapeutics stock forecast is as follows: an average price target of $69.67 (represents a 54.21% upside from SLNO’s last price of $45.18) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
SLNO Price Target
The average price target for Soleno Therapeutics (SLNO) is $69.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $74.00 to $65.00. This represents a potential 54.21% upside from SLNO's last price of $45.18.
SLNO Analyst Ratings
According to 4 Wall Street analysts, Soleno Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SLNO stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Soleno Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 02, 2024 | Raghuram Selvaraju | H.C. Wainwright | $70.00 | $50.91 | 37.51% | 54.94% |
| Oct 01, 2024 | Dae Gon Ha | Stifel Nicolaus | $74.00 | $50.49 | 46.56% | 63.79% |
| Aug 27, 2024 | Dae Gon | Stifel Nicolaus | $59.00 | $49.04 | 20.31% | 30.59% |
| Aug 27, 2024 | Leland Gershell | Oppenheimer | $65.00 | $46.76 | 39.01% | 43.87% |
| May 23, 2024 | Yasmeen Rahimi | Piper Sandler | $93.00 | $42.42 | 119.24% | 105.84% |
| May 09, 2024 | Brian Skorney | Robert W. Baird | $72.00 | $47.64 | 51.13% | 59.36% |
The latest Soleno Therapeutics stock forecast, released on Dec 02, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $70.00, which represents a 37.51% increase from the stock price at the time of the forecast ($50.91), and a 54.94% increase from SLNO last price ($45.18).
Soleno Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 6 |
| Avg Price Target | $70.00 | $72.00 | $72.17 |
| Last Closing Price | $45.18 | $45.18 | $45.18 |
| Upside/Downside | 54.94% | 59.36% | 59.74% |
In the current month, the average price target of Soleno Therapeutics stock is $70.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 54.94% increase as opposed to Soleno Therapeutics's last price of $45.18. This month's average price target is down -2.78% compared to last quarter, and down -3.01% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 03, 2024 | H.C. Wainwright | Buy | Initialise | |
| Aug 12, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 15, 2023 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 11, 2023 | Cantor Fitzgerald | Overweight | Initialise | |
| Apr 05, 2022 | Oppenheimer | Outperform | Outperform | Hold |
Soleno Therapeutics's last stock rating was published by H.C. Wainwright on Dec 02, 2024. The company gave SLNO a "Buy" rating, the same as its previous rate.
Soleno Therapeutics Financial Forecast
Soleno Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $265.00K | $447.00K | $22.00K |
| Avg Forecast | $15.59M | $7.68M | $6.40M | $5.33M | $18.83M | $10.93M | $2.56M | $200.00K | - | - | - | $22.13K | $168.64K | $548.59K | $1.20K |
| High Forecast | $15.59M | $7.68M | $6.40M | $5.33M | $18.83M | $10.93M | $2.56M | $200.00K | - | - | - | $26.56K | $202.36K | $658.31K | $1.44K |
| Low Forecast | $15.59M | $7.68M | $6.40M | $5.33M | $18.83M | $10.93M | $2.56M | $200.00K | - | - | - | $17.70K | $134.91K | $438.87K | $957.00 |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | - | - | - | 18 | 10 | 14 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.57% | 0.81% | 18.38% |
Soleno Therapeutics's average Quarter revenue forecast for Mar 18 based on 18 analysts is $22.13K, with a low forecast of $17.70K, and a high forecast of $26.56K. SLNO's average Quarter revenue forecast represents a -91.65% decrease compared to the company's last Quarter revenue of $265.00K (Mar 17).
Soleno Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | - | - | - | 18 | 10 | 14 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-3.24M | $-2.74M | $-3.17M | $-11.63M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $-5.11M | $-1.29M | $-3.76M | $-153.93M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $-4.09M | $-1.03M | $-3.00M | $-123.14M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $-6.13M | $-1.55M | $-4.51M | $-184.72M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.63% | 2.12% | 0.84% | 0.08% |
undefined analysts predict SLNO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Soleno Therapeutics's previous annual EBITDA (undefined) of $NaN.
Soleno Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | - | - | - | 18 | 10 | 14 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-3.75M | $-2.89M | $-3.19M | $-11.65M |
| Avg Forecast | $-19.26M | $-25.96M | $-27.22M | $-27.64M | $-15.43M | $-20.52M | $-25.96M | $-29.45M | $-41.88M | $-25.34M | $-21.91M | $-7.51M | $-1.36M | $-3.78M | $-154.14M |
| High Forecast | $-19.26M | $-25.96M | $-27.22M | $-27.64M | $-15.43M | $-20.52M | $-25.96M | $-27.29M | $-35.72M | $-25.34M | $-21.91M | $-6.01M | $-1.09M | $-3.02M | $-123.31M |
| Low Forecast | $-19.26M | $-25.96M | $-27.22M | $-27.64M | $-15.43M | $-20.52M | $-25.96M | $-31.19M | $-48.65M | $-25.34M | $-21.91M | $-9.01M | $-1.63M | $-4.54M | $-184.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.50% | 2.12% | 0.84% | 0.08% |
Soleno Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SLNO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Soleno Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | - | - | - | 18 | 10 | 14 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $1.87M | $1.27M | $2.48M | $1.55M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Soleno Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to SLNO last annual SG&A of $1.87M (Mar 18).
Soleno Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | - | - | - | 18 | 10 | 14 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-2.88 | $-8.06 | $-16.16 | $-125.45 |
| Avg Forecast | $-0.46 | $-0.62 | $-0.65 | $-0.66 | $-0.37 | $-0.49 | $-0.62 | $-0.70 | $-1.00 | $-0.60 | $-0.57 | $-0.46 | $-0.16 | $-1.60 | $-1.32 |
| High Forecast | $-0.46 | $-0.62 | $-0.65 | $-0.66 | $-0.37 | $-0.49 | $-0.62 | $-0.65 | $-0.85 | $-0.60 | $-0.57 | $-0.37 | $-0.13 | $-1.28 | $-1.06 |
| Low Forecast | $-0.46 | $-0.62 | $-0.65 | $-0.66 | $-0.37 | $-0.49 | $-0.62 | $-0.74 | $-1.16 | $-0.60 | $-0.57 | $-0.55 | $-0.20 | $-1.92 | $-1.59 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 6.27% | 50.40% | 10.10% | 95.04% |
According to undefined Wall Street analysts, Soleno Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SLNO previous annual EPS of $NaN (undefined).
Soleno Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics | $1.00 | $30.00 | 2900.00% | |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| ANNX | Annexon | $4.88 | $14.00 | 186.89% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| BOLT | Bolt Biotherapeutics | $0.54 | $1.00 | 85.19% | Hold |
| BNTC | Benitec Biopharma | $12.77 | $20.33 | 59.20% | Buy |
| SLNO | Soleno Therapeutics | $47.65 | $69.67 | 46.21% | Buy |
| CAPR | Capricor Therapeutics | $13.20 | $15.38 | 16.52% | Buy |